Fund+

General contacts
Investor type

PE / VC

Founded

2015

AUM

$200 M

Location

Leuven, Flemish Region, Belgium

Investment Ticket

$10-50 m

Investment Stage

Series B Series A Seed Late Stage (Series C+)

Region of investment

Europe

ESG Focus

Impact investor
Investor profile last updated: 21 August, 2026

Profile

Fund+ is a venture capital firm based in Leuven, Belgium, specializing in life sciences investments. The firm focuses on creating long-term value through equity investment in innovative life sciences companies with a particular emphasis on the Belgian market. Fund+ aims to foster leadership in the life sciences sector while delivering beneficial societal impacts. It operates as an open-ended fund, which allows it to invest with a long-term perspective, supporting portfolio companies in achieving sustainable growth and innovation.

Fund+ invests primarily in life sciences and healthtech companies, addressing diverse sub-sectors within these industries. While specific investment sizes are not disclosed, its strategy includes supporting early to mid-stage companies. Typically focused on investments in Belgium, Fund+ partners with companies that seek to create significant shareholder value while positively impacting society.

The firm's portfolio includes notable investments such as Ona Therapeutics - focused on developing first-in-class anti-tumor therapies, Tubulis - working on novel antibody-drug conjugates, and TargED Biopharmaceuticals - specializing in cardiovascular disease treatments. Other notable portfolio companies include AstriVax, Cellaion, and Coave Therapeutics, each contributing to innovative solutions in the life sciences field.

Industry

Healthcare Services Life Sciences HealthTech Biotechnology Medical Devices Pharmaceuticals MedTech

Contacts

Name
Title
Email
Social Networks
avatar
Caroline Goddeeris Venture Partner
Venture Partner
c•••@•••
LinkedIn
avatar
Bart De Leeuw Partner/CFO
Partner/CFO
b•••@•••
LinkedIn
Upgrade to see contacts
avatar
zmS0CDIdUgERTq32 zmS0CDIdUgERTq32
zmS0CDIdUgERTq32
[email protected]
linkedin twitter
avatar
zmS0CDIdUgERTq32 zmS0CDIdUgERTq32
zmS0CDIdUgERTq32
[email protected]
linkedin twitter
avatar
zmS0CDIdUgERTq32 zmS0CDIdUgERTq32
zmS0CDIdUgERTq32
[email protected]
linkedin twitter
Investment-team contacts for Fund+ — including verified work emails and LinkedIn profiles — are available to Private Equity List subscribers.
Instant access on the web. Plans from $129/month — see pricing.
Contacts sourced from the firm's website and LinkedIn, re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.

FAQs about Fund+

Fund+ is a venture capital and private equity firm. It backs companies at Series B, Series A, Seed and Late Stage (Series C+), writing tickets of $10-50 m.
Fund+ is located in Leuven, Flemish Region, Belgium.
Fund+ was founded in 2015.
Fund+ invests in companies and startups in Healthcare Services, Life Sciences, HealthTech, Biotechnology, Medical Devices, Pharmaceuticals, MedTech.
Fund+ invests in companies and startups in Europe.
Fund+ invests in companies and startups at Series B, Series A, Seed, Late Stage (Series C+).
Fund+ usually invests $10-50 m on average.
Fund+ has around $200m assets under management.
Yes, Fund+ is impact investor.
Fund+ can be reached through its website fundplus.be and its LinkedIn page. Its general enquiries address is [email protected]. Cold-mailing a general inbox rarely reaches a partner, so Private Equity List also lists the investment-team contacts for Fund+ — names, roles, verified work emails and LinkedIn profiles — available on a Pro plan from $129/month (see pricing). Contacts are sourced from the firm's website and LinkedIn and re-verified on a rolling cycle. Spot a stale contact, or none at all? Report it — we re-run that firm within 48h and get back to you.
Yes. Every field on this page — profile, funds, investment criteria, portfolio and investment-team contacts — is available programmatically through the Private Equity List REST API and MCP server, so AI assistants such as Claude and ChatGPT can query Fund+ directly instead of scraping this page. One subscription covers both the web app and machine access — see API & MCP.
Private Equity List re-verifies investor profiles on a rolling cycle, pulling from the firm's own website and LinkedIn rather than a one-off import. This profile was last updated on 21 August, 2026. Something out of date here? Report it — we re-run that firm within 48h and get back to you.